BioCentury | Jan 11, 2016
Company News
DiagnoCure, Hologic deal
...sell all assets related to the prostate cancer antigen gene 3 (PCA3) biomarker to Hologic’s Gen-Probe Inc....
...series A convertible preferred shares of DiagnoCure held by Gen-Probe valued at C$1 million ($742,633). Gen-Probe...
...cancer test in the field of high-volume in vitro diagnostics testing. Under a 2010 deal, Gen-Probe...
...series A convertible preferred shares of DiagnoCure held by Gen-Probe valued at C$1 million ($742,633). Gen-Probe...
...cancer test in the field of high-volume in vitro diagnostics testing. Under a 2010 deal, Gen-Probe...